Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant <i>Enterobacter cloacae</i>.

ABSTRACT: Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4 g Q8h), and ceftazidime-avibactam (2.5 g Q8h) against carbapenemase-producing (CP) (AR-1046_blaKPC-3) and non-CP (AR-8_{bla ACT-15}) Enterobacter cloacae isolates in a 120 h in vitro pharmacodynamic model. Additionally, we compared antimicrobial administration as a bolus or extended infusion for each isolate and treatment. For the CP strain, all treatments with meropenem-vaborbactam and ceftazidime-avibactam were bacteriostatic through 24 h. Extended-infusion merope

SUBMITTER: Lavoie T 

PROVIDER: S-EPMC12691640 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature